pipeline
Alzheimer’s program
Currently, over 55 million people worldwide are living with dementia, a number projected to reach 78 million by 2030 and 139 million by 2050. Alzheimer’s disease (AD) is by far the most common form of dementia, affecting one in nine people aged 65 and older. It is also the 6th leading cause of death.
At a pathological level, Alzheimer’s is characterized by the accumulation of amyloid-beta (Aβ) plaques and tau fibrillary tangles. These abnormalities lead to synaptic loss and neuronal degeneration, causing symptoms such as memory loss and cognitive decline that severely disrupt daily life for both patients and caregivers. A dysregulation of Calcium (Ca²⁺) homeostasis is one of the drivers of this disease process, contributing to synaptic dysfunction and Aβ/tau pathology.
The Alzheimer’s disease therapeutics market is currently valued at approximately $4 billion USD and expected to grow to $15 billion by 2030. But current treatment options, including the most recently developed drugs, have limited efficacy. These treatments slow the disease process by ~25%, an effect that has very limited impact on the lives of patients and caregivers. Drugs addressing both AD symptoms as well as the underlying disease process are not currently available.
remynd’s lead program consists of an orally available small molecule, REM392, designed to rescue the detrimental effect of pathological tau on calcium homeostasis. As such, REM392 addresses a core element in the Alzheimer’s disease cascade. By intervening at this fundamental level, we help prevent the build-up of Aβ plaques and tau tangles, protect synaptic function, and reduce neuronal loss. Our preclinical and clinical data suggest that this mechanism has the unique potential to offer both symptomatic relief and disease modification, which will truly change the lives of patients and caregivers. The dual mechanism has the added benefit of shorter clinical development timelines than typical in the field.
Published in Science.
Picked up by BioCentury, BioWorld, Nature Reviews Drug Discovery and local news.
https://youtu.be/SfRAfVxq0aM
